Showing results (401-410 of 555) with videos related to
Sort By:
Pageof 56
Journal of the American Academy of Dermatology|August 27, 2025
Chronic skin conditions and life trajectories: development and validation of "Dermatology Long-Term Life Impact Measure (DLLIM)"Jonathan I Silverberg, Charbel Skayem, Ann'Laure Demessant Flavigny, et al.Lancet (London, England)|May 23, 2021
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trialKristian Reich, Henrique D Teixeira, Marjolein de Bruin-Weller, et al.Dermatology and Therapy|September 23, 2025
Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?Eric L Simpson, Jonathan I Silverberg, Bob Geng, et al.Journal of the American Academy of Dermatology|January 27, 2022
American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adultsDawn M R Davis, Aaron M Drucker, Ali Alikhan, et al.Dermatitis : Contact, Atopic, Occupational, Drug|September 18, 2020
Measurement Properties of 4 Patient-Reported Outcome Measures to Assess Sleep Disturbance in Adults With Atopic DermatitisDonald K Lei, Muhammad Yousaf, Sherief R Janmohamed, et al.American Journal of Clinical Dermatology|May 2, 2024
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 StudiesLawrence F Eichenfield, Eric L Simpson, Kim Papp, et al.The British Journal of Dermatology|October 22, 2024
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up)Jonathan I Silverberg, Christopher G Bunick, H Chih-Ho Hong, et al.Dermatology and Therapy|June 18, 2026
Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)Emma Guttman-Yassky, Alan D Irvine, Melinda Gooderham, et al.Plos One|August 4, 2022
Predictors of chronic COVID-19 symptoms in a community-based cohort of adultsJonathan I Silverberg, Israel Zyskind, Hiam Naiditch, et al.JAMA Network Open|March 10, 2021
SARS-CoV-2 Seroprevalence and Symptom Onset in Culturally Linked Orthodox Jewish Communities Across Multiple Regions in the United StatesIsrael Zyskind, Avi Z Rosenberg, Jason Zimmerman, et al.Pageof 56